A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 442 participants.
Also called NCT01555164
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 442 participants
- Sponsor
- Registry
-
NCT01555164 -
2012-001259-37
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, Hungary, India, Israel, Mexico, Poland, Russia, South Africa, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01555164. Randomized; double masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-09 (actual). Results posted on 2014-09-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study of Ranolazine in Subjects With Type 2 Diabetes Who Are Inadequately Controlled on Metformin Alone
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ranolazine
- Intervention (Drug)
- Placebo to match ranolazine
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo to match metformin
- Intervention (Behavioral)
- Diet
- Intervention (Behavioral)
- Exercise
- Lead sponsor
- Gilead Sciences
Record details
- Record id
cardio:ct-nct01555164- Content hash
1ab49d023262cce53f8787e812a28983870cdd3c1162afd656bb5746b04465ca